IMPORTANTTo read the national and local advice about coronavirus, please click
HERE
Contact
Open Hours
LOGIN/LOGOUT
Vaccines
Destinations
General
Need some help?
Email Us
Ambulance
999
NHS
111
Daisy Hill Hospital GP out of hours phone no:
028 383 99201
Fax :
0044 (0) 28 30265677
Online Shopping
0300 303 3380
Pharmacy
McNally's Late Night Pharmacy
0044 (0) 28 3026 2110
Social
Facebook
* Please be advised that we record all incoming and outgoing calls. This is for training and quality purposes and to protect both our staff and patients
Usual
Opening Hours
Monday
09:00 to 22:00
Tuesday
09:00 to 22:00
Wednesday
09:00 to 22:00
Thursday
09:00 to 22:00
Friday
09:00 to 22:00
Saturday
09:00 to 20:00
Sunday
09:00 to 18:00
Holiday
Opening Hours
Our opening hours may vary from branch to branch. Visit our branches page to see the opening hours of your nearest branch.
See Branches
Cholera
Diphtheria
Hepatitis A
Hepatitus B
Japanese Encephalitis
Meningitis A,C,W, and Y
Polio
Rabies
Tetanus
Tick-borne Encephalitis
Typhoid
Yellow Fever
Africa
Antarctica
Asia
Australia & Pacific
Caribbean
Central America
Europe
Middle East
North America
South America
BLOGS
What we have to say about your health and well being
Search...
BLOG
What we have to say about your health and well being
30
Jul 2014
Revolutionary new blood test 'could detect ALL types of cancer'
A revolutionary blood test that could detect any type of cancer has been developed by British scientists. It is hoped the breakthrough will enable doctors to rule out cancer in patients presenting with certain symptoms - saving time and preventing costly and unnecessary invasive procedures and biopsies. Early results have shown the simple test can diagnose cancer and pre-cancerous conditions from the blood of patients with melanoma, colon cancer and lung cancer with a high degree of accuracy. The test has been able to diagnose cancer and pre-cancerous conditions from the blood of patients with the disease in their skin, colon or lungs. Alternatively, it could be a useful aid for investigating patients who are suspected of having a cancer that is currently hard to diagnose, say the University of Bradford researchers. The Lymphocyte Genome Sensitivity (LGS) assesses white blood cells and measures the damage caused to their DNA when subjected to different intensities of ultraviolet light (UVA), which is known to damage DNA. The Bradford scientists say there is a 'clear distinction between the damage to the white blood cells from patients with cancer, with pre-cancerous conditions and from healthy patients'. Research leader Professor Diana Anderson, from the University’s School of Life Sciences, said: 'White blood cells are part of the body’s natural defence system. 'We know that they are under stress when they are fighting cancer or other diseases, so I wondered whether anything measureable could be seen if we put them under further stress with UVA light.
'We found that people with cancer have DNA which is more easily damaged by ultraviolet light than other people.' The conclusions were drawn after looking at the blood samples of 208 people - 94 were healthy members of university staff and students. The other 114 were collected from patients referred to specialist clinics within Bradford Royal Infirmary prior to diagnosis and treatment. UVA damage was observed in the form of pieces of DNA being pulled in an electric field towards the positive end of the field, causing a comet-like tail. The test centres around damage to white blood cells (pictured). The researchers say there is a 'clear distinction between the damage to the cells or those with or without cancer. The longer the tail, the more DNA damage. And these measurements correlated to those patients who were ultimately diagnosed with cancer (58), those with pre-cancerous conditions (56) and those who were healthy (94). 'These are early results completed on three different types of cancer and we accept that more research needs to be done; but these results so far are remarkable,' said Professor Anderson. She added that while the numbers tested were small, the 'results are powerful'. The research is published online in FASEB Journal, the U.S. Journal of the Federation of American Societies for Experimental Biology.
The test's accuracy is now being investigated in a clinical trial at Bradford Royal Infirmary with patients suspected to have colorectal cancer. A patent has been filed for the technology and a spin-out company, Oncascan, has been established to commercialise the research.
CONTACT
5 Monaghan Street, Co Down Newry County Armagh BT35 6BB